Cipla shares trade flat after pharma major's Indore unit gets warning letter from USFDA

Cipla share price NSE, Cipla Pithampur facility Indore news: Cipla shares edged lower on Monday, November 20, after the Mumbai-based drugmaker's facility in Pithampur, Indore, received a warning letter from the United States Food and Drug Administration (USFDA). The stock declined as much as over 0.5 per cent to touch the day's low of Rs 1,241 on the NSE in early morning deals. The warning letter dated November 17 is based on the inspection carried out between February 6 and February 17, 2023.

Cipla shares ended flat at 1,248.75, down 0.05 per cent on NSE.

The company mentioned that the warning letter summarises contraventions regarding methods or controls followed at the facility that do not follow Current Good Manufacturing Practices (CGMP) and contains directional guidance for necessary corrections. The pharma major will respond to the USFDA within the stipulated time to ensure sustained compliance, the company said in its regulatory filing.

For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com